The management of PS2 patients with advanced non-small cell lung cancer

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1493-1496

  Cheong, Kerry A ^a,b   Chrystal, K ^a   Harper, P G ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b Ashford Cancer Centre   (Australia)

Author keywords

Chemotherapy; NSCLC; PS2

Indexed keywords

CELECOXIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; EVIDENCE BASED MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 33749836693     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00878.x     Document Type: Review

References (29)

1. Page N, Read W, Tierney R. The epidemiology of small cell lung cancer. Proc Am Soc Clin Oncol. 2002; 21: 305a.
2. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220-4.
3. Roila F, Lupattelli M, Sassi M et al. Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 1991; 2: 437-9.
4. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4: 14-22.
5. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 2002; 38 (Suppl. 2): S45-50.
6. Hesketh PJ et al. Sequential vinorelbine and docetaxwl in advanced non-small cell lung cancer (NSCLC) patients age >70, or with performance status (PS) 2: A SWOG phase II trial (S0027). Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
7. Hainsworth JD, Burris HA III, Litchy S et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Res Network Phase II Trial. Cancer 2000; 89: 328-33.
8. Chaplen RA et al. Celocoxib and weekly docetaxel in elderly or PS2 patients with advanced non-small cell lung cancer (NSCLC). Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
9. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
10. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
11. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447-53.
12. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-80.
13. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
14. Sweeney CJ, Zhu J, Sandler AB et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A Phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001; 92: 2639-47.
15. Lilenbaum RC, Herndon JE, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-6.
16. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001; 12: 1671-5.
17. Rudd RM, Gower NH, Spiro SG et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: A phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23: 142-53.
18. Langer C, Stephenson P, Schiller J et al. ECOG 1599: Randomized phase II trial of paclitaxel-carboplatin or gemcitabine-cisplatin in PS2 patients with advanced NSCLC. Lung Cancer 2003; 41 (Suppl. 2): S18.
19. Kosmidis P et al. Gemcitabine vs gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and PS2. A prospective randomized phase II study of the Hellenic Co-Operative Group. Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
20. Sandbach JF et al. A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients aged <65 and performance status 2. Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
21. Langer CJ et al. Paclitaxel poliglumex/carboplatin vs paclitaxel/ carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer: A phase III study. Proceedings of American Society of Clinical Oncology 2005, Orlando, Florida.
22. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
23. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-58.
24. Shepherd FA et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
25. Zinner R et al. Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP). Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
26. Ervin TJ, Toothaker SR. Community practice experience with gefitinib (ZD1839) as treatment for patients with advanced non-small-cell lung cancer (NSCLC) within an expanded access clinical program. Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.
27. Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003; 89: 1827-9.
28. Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43: 317-22.
29. Dickson N et al. Single agent gefitinib in poor performance status patients with previously untreated advanced non-small-cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial. Proceedings of American Society of Clinical Oncology 2004, New Orleans, Louisiana.